
According to Benzinga Pro data, during Q4, LogicBio Therapeutics (NASDAQ:LOGC) posted sales of $2.03 million. Earnings were up 11.02%, but LogicBio Therapeutics still reported an overall loss of $9.06 million. In Q3, LogicBio Therapeutics brought in $2.12 million in sales but lost $10.19 million in earnings.